Cytokinetics, Incorporated

Total revenue in Q2 2026 was $28.6 million versus $66.8 million in Q2 2025. Net product revenue from MYQORZO was $25.3 million, including $23.0 million in the U.S. and $2.3 million in Europe; collaboration revenue was $3.3 million versus $2.4 million a year ago, and no licensing or milestone revenue was recorded versus $64.4 million in Q2 2025. R&D expense was $97.8 million versus $110.1 million, SG&A was $104.4 million versus $65.7 million, and net loss was $198.8 million, or $1.50 per share, versus a net loss of $134.4 million, or $1.12 per share. Cash and investments ended the quarter at approximately $1.7 billion, up from $1.1 billion at the end of Q1, helped by approximately $760 million in net proceeds from the May public offering. Full-year 2026 GAAP combined R&D and SG&A guidance was raised to $860 million-$890 million from $830 million-$870 million; stock-based compensation guidance moved to $130 million-$140 million, and excluding stock-based compensation the range is $720 million-$760 million.

Robert Blum framed the quarter as another period of execution, emphasizing strong U.S. commercial momentum for MYQORZO, the first European launch in Germany, and progress toward broader international access. He highlighted ACACIA-HCM as an important scientific step that could expand aficamten into nHCM, and said the company is positioning MYQORZO to become the CMI of choice in oHCM. His tone was confident but measured, repeatedly stressing disciplined capital allocation and a strong balance sheet.

Sung Lee focused on the reported financials and the drivers behind them. He noted that MYQORZO net product revenue was $25.3 million, that SG&A rose to $104.4 million mainly from launch costs and the U.S. sales force, and that R&D was $97.8 million. He also pointed to the $1.7 billion cash and investments balance, boosted by about $760 million in net proceeds from the May offering, and explained that the higher full-year expense guidance reflects commercial readiness investments for a potential 2027 nHCM launch.

Analysts focused heavily on the gap between prescriptions and dispenses, and management explained that most of the difference is a normal process delay tied to REMS enrollment, benefits investigation, and prior authorization, with only a small number of cancellations. Questions also centered on what drives MYQORZO share gains, and Andrew Callos said growth is coming from both high-volume physicians and broader adoption among low-volume and first-time CMI prescribers, with switching still only about 5% to 7% of dispenses. Several questions addressed how ACACIA-HCM, MAPLE-HCM, and a potential nHCM label expansion could affect prescribing, and management said those data should broaden the physician view of appropriate patients, though the impact will likely build over time rather than cause an immediate surge.